Table of E3311 Trial Results (IMAGE) ECOG-ACRIN Cancer Research Group Caption The randomized phase 3 study E3311 by the ECOG-ACRIN Cancer Research Group met its primary endpoint, showing an improvement in two-year progression-free survival in patients determined to be at intermediate risk of recurrence after surgical excision. For intermediate risk patients-those with uninvolved surgical margins, less than five involved nodes, and less than 1mm extranodal extension-reduced-dose postoperative radiation therapy without chemotherapy appears sufficient. In our study, this group had better outcomes than the group on usual high-dose radiation plus chemotherapy, showing that our patient stratification identified low and intermediate risk patients well, preserving patients' throat function and sparing them unnecessary short- and long-term toxicities. Credit ECOG-ACRIN Cancer Research Group Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.